EUVIMEDEUVIMED entdecken
Crossref

SEW2871 reduces seizures via the sphingosine 1‐phosphate receptor‐1 pathway in the pentylenetetrazol and phenobarbitone kindling model of drug‐refractory epilepsy

Ashish Jain iD, Arti Ralta, Gitika Batra, Rupa Joshi, Nitika Garg, Alka Bhatia iD, Bikash Medhi iD, Amitava Chakrabarti, Ajay Prakash iD

Clinical and Experimental Pharmacology and Physiology · 2024

DOI: 10.1111/1440-1681.13839 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Pharmacology and Physiology, 2024. Verfasst von Ashish Jain und 8 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Pharmacology Laboratory, Neurobehavioral Research Laboratory, Department of Pharmacology, PGIMER, Chandigarh, India. Hauptthemen laut MEDLINE: Drug Resistant Epilepsy, Epilepsy, Oxadiazoles, Thiophenes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Postgraduate Institute of Medical Education and Research, Chandigarh.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epilepsy is a prevalent neurological disorder characterized by neuronal hypersynchronous discharge in the brain, leading to central nervous system (CNS) dysfunction. Despite the availability of anti‐epileptic drugs (AEDs), resistance to AEDs is the greatest challenge in treating epilepsy. The role of sphingosine‐1‐phosphate‐receptor 1 (S1PR1) in drug‐resistant epilepsy is unexplored. This study investigated the effects of SEW2871, a potent S1PR1 agonist, on a phenobarbitone (PHB)‐resistant pentylenetetrazol (PTZ)‐kindled Wistar rat model. We measured the messenger ribonucleic acid (mRNA) expression of multi‐drug resistance 1 (MDR1) and multi‐drug resistance protein 5 (MRP5) as indicators for drug resistance. Rats received PHB + PTZ for 62 days to develop a drug‐resistant epilepsy model. From day 48, SEW2871 (0.25, 0.5, 0.75 mg/kg, intraperitoneally [i.p.]) was administered for 14 days. Seizure scoring, behaviour, oxidative markers like reduced glutathione, catalase, superoxide dismutase, inflammatory markers like interleukin 1 beta tumour necrosis factor alpha, interferon gamma and mRNA expression (MDR1 and MRP5) were assessed, and histopathological assessments were conducted. SEW2871 demonstrated dose‐dependent improvements in seizure scoring and neurobehavioral parameters with a reduction in oxidative and inflammation‐induced neuronal damage. The S1PR1 agonist also downregulated MDR1 and MRP5 gene expression and significantly decreased the number of dark‐stained pyknotic nuclei and increased cell density with neuronal rearrangement in the rat brain hippocampus. These findings suggest that SEW2871 might ameliorate epileptic symptoms by modulating drug resistance through downregulation of MDR1 and MRP5 gene expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistant EpilepsyEpilepsyOxadiazolesThiophenesRatsAnimalsPentylenetetrazolePhenobarbitalSphingosine-1-Phosphate ReceptorsRats, WistarSeizuresRNA, Messenger

Stichwörter der Autor:innen

S1PR1SEW2871Wistar ratsdrug-refractory epilepsygene regulation expressionhippocampusmulti-drug resistancemulti-drug resistance proteinneuronal damage

Substanzen

PentylenetetrazoleSEW2871PhenobarbitalSphingosine-1-Phosphate ReceptorsRNA, MessengerOxadiazolesThiophenes

Autor:innen und Institutionen

  • Experimental Pharmacology Laboratory, Neurobehavioral Research Laboratory, Department of Pharmacology, PGIMER, Chandigarh, India.
  • Department of Neurology, PGIMER, Chandigarh, India.
  • Department of Pharmacology, Maharishi Markandeshwar Institute of Medical Science and Research, Ambala, India.
  • Department of Experimental Medicine and Biotechnology, PGIMER, Chandigarh, India.

ORCID-Profile: Ashish Jain, Alka Bhatia, Bikash Medhi, Ajay Prakash

Förderung

  • Postgraduate Institute of Medical Education and Research, Chandigarh

Zitieren

APA

Jain, A., Ralta, A., Batra, G., Joshi, R., Garg, N., Bhatia, A., Medhi, B., Chakrabarti, A., & Prakash, A. (2024). SEW2871 reduces seizures via the sphingosine 1‐phosphate receptor‐1 pathway in the pentylenetetrazol and phenobarbitone kindling model of drug‐refractory epilepsy. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1111/1440-1681.13839

Vancouver

Jain A, Ralta A, Batra G, Joshi R, Garg N, Bhatia A, et al. SEW2871 reduces seizures via the sphingosine 1‐phosphate receptor‐1 pathway in the pentylenetetrazol and phenobarbitone kindling model of drug‐refractory epilepsy. Clinical and Experimental Pharmacology and Physiology. 2024. doi:10.1111/1440-1681.13839

BibTeX
@article{Jain2024,
  author = {Jain, Ashish and Ralta, Arti and Batra, Gitika and Joshi, Rupa and Garg, Nitika and Bhatia, Alka and Medhi, Bikash and Chakrabarti, Amitava and Prakash, Ajay},
  title = {SEW2871 reduces seizures via the sphingosine 1‐phosphate receptor‐1 pathway in the pentylenetetrazol and phenobarbitone kindling model of drug‐refractory epilepsy},
  journal = {Clinical and Experimental Pharmacology and Physiology},
  year = {2024},
  doi = {10.1111/1440-1681.13839}
}
Kostenlos starten →